Lisa Girion's slides from the Center for Health Journalism webinar, "Reporting on America’s Opioid Drug Crisis," 4.11.17
More info: https://www.centerforhealthjournalism.org/content/reporting-americas-opioid-drug-crisis
Dr. Andrew Kolodny: "Reporting on America’s Opioid Drug Crisis" 4.11.17reportingonhealth
Dr. Andrew Kolodny's slides from the Center for Health Journalism webinar, "Reporting on America’s Opioid Drug Crisis," 4.11.17
More info: http://www.centerforhealthjournalism.org/content/after-obamacare-future-us-health-care
Prof. Keith Humphreys: "Profiteers of Tragedy: Making Money Off America’s Opi...reportingonhealth
Prof. Keith Humphreys' slides from the Center for Health Journalism webinar, "Profiteers of Tragedy: Making Money Off America’s Opioid Addicts," 10.31.17
More info: https://www.centerforhealthjournalism.org/content/profiteers-tragedy-making-money-americas-opioid-addicts
The document summarizes polling data and research on the use of medical marijuana to treat fibromyalgia. Some key findings include: 42% of fibromyalgia patients have tried cannabis for relief, with 62% finding it more effective than prescription drugs. However, 58% have not tried it due to legal concerns, side effects, or stigma. The majority see prescription drugs as ineffective and many seek alternatives like medical marijuana. Research on cannabis for fibromyalgia is still limited, but anecdotal evidence suggests it may help treat the chronic pain associated with the condition.
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Prescription drug abuse, especially of opioids, is a major problem in the United States, with millions of Americans misusing controlled prescription drugs each year. The misuse of pharmaceuticals has increased significantly while the abuse of illicit drugs has remained steady. While prescription drugs serve important medical purposes, widespread non-medical use has led to a rise in emergency room visits, overdose deaths, and admissions for treatment of prescription drug abuse. Coordinated efforts are needed across healthcare, law enforcement, and community levels to address this epidemic.
1. The study examined whether racial/ethnic differences exist in the diagnosis of Parkinson's disease (PD) among a Medicaid population in Pennsylvania from 1998-2003.
2. It found that middle-aged black Medicaid enrollees were diagnosed with PD at half the rate of whites, even after controlling for factors like age, gender, location of care, and healthcare utilization.
3. Racial differences in PD diagnosis rates were not fully explained by income, insurance access, or healthcare use, and may be influenced by other factors related to accessing and navigating the healthcare system, as well as potential physician bias.
1. The document discusses how drug companies have helped construct the medical condition of Female Sexual Dysfunction (FSD) by influencing its definition, inflating prevalence estimates, and developing diagnosis tools and education programs.
2. Studies finding higher prevalence of FSD have largely been funded by drug companies, while non-industry studies find lower rates.
3. Drugs to treat FSD conditions like Hypoactive Sexual Desire Disorder (HSDD) have not proven effective and may carry health risks, yet drug companies continue direct-to-consumer campaigns to promote "diseases" and treatments.
Dr. Andrew Kolodny: "Reporting on America’s Opioid Drug Crisis" 4.11.17reportingonhealth
Dr. Andrew Kolodny's slides from the Center for Health Journalism webinar, "Reporting on America’s Opioid Drug Crisis," 4.11.17
More info: http://www.centerforhealthjournalism.org/content/after-obamacare-future-us-health-care
Prof. Keith Humphreys: "Profiteers of Tragedy: Making Money Off America’s Opi...reportingonhealth
Prof. Keith Humphreys' slides from the Center for Health Journalism webinar, "Profiteers of Tragedy: Making Money Off America’s Opioid Addicts," 10.31.17
More info: https://www.centerforhealthjournalism.org/content/profiteers-tragedy-making-money-americas-opioid-addicts
The document summarizes polling data and research on the use of medical marijuana to treat fibromyalgia. Some key findings include: 42% of fibromyalgia patients have tried cannabis for relief, with 62% finding it more effective than prescription drugs. However, 58% have not tried it due to legal concerns, side effects, or stigma. The majority see prescription drugs as ineffective and many seek alternatives like medical marijuana. Research on cannabis for fibromyalgia is still limited, but anecdotal evidence suggests it may help treat the chronic pain associated with the condition.
Dr. Tom Frieden, Director of the Centers for Disease Control and Prevention, keynote presentation at the National Rx Drug Abuse & Heroin Summit on March 30, 2016.
Prescription drug abuse, especially of opioids, is a major problem in the United States, with millions of Americans misusing controlled prescription drugs each year. The misuse of pharmaceuticals has increased significantly while the abuse of illicit drugs has remained steady. While prescription drugs serve important medical purposes, widespread non-medical use has led to a rise in emergency room visits, overdose deaths, and admissions for treatment of prescription drug abuse. Coordinated efforts are needed across healthcare, law enforcement, and community levels to address this epidemic.
1. The study examined whether racial/ethnic differences exist in the diagnosis of Parkinson's disease (PD) among a Medicaid population in Pennsylvania from 1998-2003.
2. It found that middle-aged black Medicaid enrollees were diagnosed with PD at half the rate of whites, even after controlling for factors like age, gender, location of care, and healthcare utilization.
3. Racial differences in PD diagnosis rates were not fully explained by income, insurance access, or healthcare use, and may be influenced by other factors related to accessing and navigating the healthcare system, as well as potential physician bias.
1. The document discusses how drug companies have helped construct the medical condition of Female Sexual Dysfunction (FSD) by influencing its definition, inflating prevalence estimates, and developing diagnosis tools and education programs.
2. Studies finding higher prevalence of FSD have largely been funded by drug companies, while non-industry studies find lower rates.
3. Drugs to treat FSD conditions like Hypoactive Sexual Desire Disorder (HSDD) have not proven effective and may carry health risks, yet drug companies continue direct-to-consumer campaigns to promote "diseases" and treatments.
This document summarizes research priorities and findings from the National Institute on Drug Abuse (NIDA) regarding the opioid crisis. It outlines NIDA's focus on alternative pain treatments, preventing opioid use disorder and overdoses, improving treatment for opioid use disorder, and implementing evidence-based solutions. Specific areas of research discussed include biomarkers for pain, abuse-deterrent drug formulations, non-medication pain treatments, universal prevention programs for adolescents, easier-to-use naloxone for overdose reversal, new formulations of addiction medications, increasing access to medication-assisted treatment, and using addiction medications earlier to prevent heroin overdoses and improve treatment retention.
The document discusses the importance of the pharmaceutical industry to Europe. It summarizes that the industry directly employs over 630,000 people in Europe and contributes 3.5% of EU manufacturing value. It is one of the few remaining high-technology industries in Europe. The industry also plays a dual role as a major economic contributor and in improving health outcomes for European citizens. However, access to new medicines remains a challenge due to the high costs of research and regulatory hurdles.
The document discusses disease awareness campaigns by pharmaceutical companies in Europe. It notes that while EU law prohibits direct advertising of prescription drugs to the public, companies use unbranded campaigns to indirectly promote their products. Several case studies of campaigns are presented that stretch and violate ethical guidelines by inappropriately fear-mongering about diseases and implying the need for specific brand-name drugs without disclosing risks. The document calls for regulatory agencies to better screen such campaigns and ensure companies are not using social media for disguised drug advertising.
This document discusses inappropriate prescribing in hospitalized elderly patients. It defines inappropriate prescribing as using medications that significantly increase the risk of adverse drug events when safer alternatives exist. Inappropriate prescribing is common in the elderly and associated with increased morbidity, mortality and healthcare costs. Risk factors in hospitals include advanced age, polypharmacy due to multiple comorbidities, and transitions of care involving multiple providers. The document reviews validated tools to evaluate inappropriate prescribing, including Beers Criteria, IPET, STOPP and MAI. It concludes inappropriate prescribing in hospitals is an important public health problem given the aging population.
This document discusses the aggressive marketing tactics used by pharmaceutical companies to promote the use of antidepressants, especially SSRIs like Paxil. It describes how companies expanded disease definitions, ignored safety issues, and promoted the drugs to vulnerable groups like pregnant women to significantly increase profits. The document argues that regulation and information systems have failed and that promotion has become disconnected from science. It calls for learning from these issues to better regulate drug licensing, promotion, and ensure independent information for physicians and consumers.
The document summarizes guidelines for providing information about diseases and prescription medicines to the public in the Netherlands. It outlines the Dutch regulatory system for pharmaceutical advertising and promotion. The guidelines were developed in response to increased disease awareness campaigns and public demand for prescription medicine information. They establish standards for balanced, complete information about diseases and technical information about prescription medicines. The guidelines apply to all parties providing such information and include conditions like not misleading the public or leading to unnecessary medical treatment. A transitional period was provided for adjusting existing information to the new guidelines.
Web only rx16 len wed_1230_1_daugherty_2baier-haasOPUNITE
This document summarizes a presentation on investigating and prosecuting drug-related homicides. It discusses signs that can indicate an overdose death, such as the presence of drugs, track marks, and foam coming from the mouth. It emphasizes treating the death scene like a homicide scene by thoroughly photographing and collecting all potential evidence. This includes searching for drug packaging, needles, phones and surveillance footage. The document also outlines interviewing witnesses to build a timeline and identify the victim's source of drugs. It suggests attempting a controlled buy from suspects to obtain contemporaneous drug samples and strengthen cases.
This document discusses addiction to prescription painkillers and the role that doctors play. It provides background on a 2011 pharmacy shooting committed by David Laffer, a prescription painkiller addict, who had been prescribed over 4,000 pills in the first half of the year. This led to investigations of the prescribing doctors. The document argues that while doctors fulfill their duty to treat patients' pain, they can also indirectly cause addiction. However, addicted patients also manipulate doctors to maintain their drug supply. Therefore, both doctors and patients share blame. It notes the taboo nature of discussing both addiction and doctors' involvement due to the high status of medicine. In the end, some doctors in the Laffer case were arrested, showing that
Relationship Between Drugs and Health Workers - Sample Essaya1customwritings
A1CustomWritings.com are experienced in all academic levels of assignments and in any academic fields, the team of experts of our custom essay writing service have the ability to help you with any requirements of your essay. Our team takes pride in the quality of work provided to our customers and we pledge to do whatever it takes to ensure you receive a paper of only the highest quality.
This document discusses strategies to curb prescription drug abuse, specifically opioid abuse, in West Virginia. It notes that West Virginia has the highest drug overdose mortality rate in the US and clinicians there write a high number of opioid prescriptions. It explores reasons for high prescribing rates and discusses solutions like improving education for patients and doctors, changing financial incentives, using prescription drug monitoring programs, and following CDC guidelines for safer opioid prescribing. Alternative therapies for pain management and the role of EDIE in monitoring patients and interfacing with PDMPs are also covered. The document advocates for internal referrals to pain specialists and multidisciplinary approaches to pain care.
This document discusses drugs for rare diseases. It begins by defining rare diseases according to different organizations. Rare diseases are individually rare but collectively common, affecting around 6-8% of the global population. Developing drugs for rare diseases is challenging due to the small patient populations and high costs. Governments provide incentives like tax breaks and exclusive rights to encourage pharmaceutical companies to develop orphan drugs. Recent advances in genetics have helped identify causes of many rare diseases and accelerated drug development. While treatment options have increased in recent decades, more understanding and viable treatments are still needed for most rare diseases.
This document discusses orphan drugs, which treat rare diseases. It defines orphan drugs and outlines criteria used in the US and EU to designate drugs for rare diseases. Rare diseases affect fewer than 200,000 people in the US and 10,000 in the EU. The Orphan Drug Act of 1983 in the US provided incentives for orphan drug development. Similar laws exist in other countries. Developing orphan drugs is challenging due to low patient populations and high costs. Examples of orphan drugs and their manufacturers are provided. The process for obtaining orphan drug designation is also summarized.
The document summarizes a study examining HIV stigma among opioid-dependent individuals under community supervision. It describes high HIV rates in Washington D.C. and the criminal justice system. The study used a stigma scale to assess stigma in 16 participants. Females and homosexuals reported higher levels of stigma than males and heterosexuals, particularly around disclosure concerns. The study aims to reduce stigma and HIV risk through counseling in Project STRIDE, which provides medication-assisted treatment for opioid dependence and HIV.
The document discusses efforts to address the opioid epidemic in the United States, including:
- Increasing registration and use of prescription drug monitoring programs (PDMPs) to track opioid prescriptions.
- Reducing the stigma around both pain and substance use disorder to increase access to comprehensive treatment.
- Expanding access to naloxone to prevent overdose deaths and "Good Samaritan" legal protections.
- Ongoing education of physicians on safe opioid prescribing and alternative pain management strategies.
This document is an undergraduate thesis that examines the pharmaceutical industry and alternative medicine. It argues that while Western medicine has improved health outcomes for some acute illnesses, the over-reliance on drugs has significant downsides. Preventable medical errors are the third leading cause of death in the US, with pharmaceutical companies more focused on profits than patient safety. The document also suggests that several holistic doctors working on alternative cancer treatments may have been murdered to protect the financial interests of the pharmaceutical industry.
Bacchus 2015 Presentation - Prescription Drugs on College Campuses: A Slipper...Ally Siegler
This presentation was given at The BACCHUS Network General Assembly 2015 by Ally Siegler, Trevor Fain, and Elisabeth Weber. It highlights the growing problem of prescription drug abuse on college campuses and what peer health education programs can do to combat the issue.
Kristen Sismilich created a patient education tool for veterans undergoing chemotherapy at the Baypines VA Hematology/Oncology Clinic. The tool provides pictures and descriptions of common chemotherapy side effects and signs/symptoms that require immediate medical attention. Nurses and patients responded positively to the tool. While the tool still needs approval from the VA, its goal is to improve patient health outcomes and appropriate use of healthcare services by enhancing health literacy as outlined in Healthy People 2020 objectives. Low health literacy is associated with poorer health outcomes and healthcare utilization according to research.
West Virginia has high rates of opioid and benzodiazepine prescription and misuse according to the document. It ranks third highest for opioid prescriptions per capita and first for benzodiazepine prescriptions. In 2014 over 400,000 opioid prescriptions and 300,000 benzodiazepine prescriptions were filled for West Virginia Medicaid recipients. West Virginia Medicaid has policies like quantity limits and a lock-in program to curb prescription drug abuse and encourages providers and recipients to follow best practices for responsible prescribing and use.
Physicians, especially anesthesiologists, face high risks of addiction due to easy access to addictive drugs. While medical boards discipline doctors with reported drug problems, random drug testing is rare, allowing issues to surface only when problems are severe. Addiction to opioids is most common, with fentanyl and sufentanil frequently abused by anesthesiologists due to impaired thinking. More data and proactive random drug testing are needed to address this ongoing problem impacting patient care.
Club Drug Clinic, Project Neptune and the G TrialReShape
This document discusses the Club Drug Clinic and two of its projects: NEPTUNE and the GHB Trial. The Clinic treats patients with issues related to emerging drugs like novel psychoactive substances and club drugs. Project NEPTUNE aims to improve clinical management of these substances through evidence-based guidance. The GHB Trial is a feasibility study testing whether adding the drug baclofen to benzodiazepines improves outcomes for patients withdrawing from GHB dependence.
The document discusses various strategies to reduce unnecessary healthcare costs and improve quality, including reducing overuse of procedures, tests, drugs and hospitalizations through evidence-based guidelines and promoting primary care. It notes that higher spending regions do not achieve better health outcomes and that up to 30% of healthcare spending is wasteful.
This document summarizes research priorities and findings from the National Institute on Drug Abuse (NIDA) regarding the opioid crisis. It outlines NIDA's focus on alternative pain treatments, preventing opioid use disorder and overdoses, improving treatment for opioid use disorder, and implementing evidence-based solutions. Specific areas of research discussed include biomarkers for pain, abuse-deterrent drug formulations, non-medication pain treatments, universal prevention programs for adolescents, easier-to-use naloxone for overdose reversal, new formulations of addiction medications, increasing access to medication-assisted treatment, and using addiction medications earlier to prevent heroin overdoses and improve treatment retention.
The document discusses the importance of the pharmaceutical industry to Europe. It summarizes that the industry directly employs over 630,000 people in Europe and contributes 3.5% of EU manufacturing value. It is one of the few remaining high-technology industries in Europe. The industry also plays a dual role as a major economic contributor and in improving health outcomes for European citizens. However, access to new medicines remains a challenge due to the high costs of research and regulatory hurdles.
The document discusses disease awareness campaigns by pharmaceutical companies in Europe. It notes that while EU law prohibits direct advertising of prescription drugs to the public, companies use unbranded campaigns to indirectly promote their products. Several case studies of campaigns are presented that stretch and violate ethical guidelines by inappropriately fear-mongering about diseases and implying the need for specific brand-name drugs without disclosing risks. The document calls for regulatory agencies to better screen such campaigns and ensure companies are not using social media for disguised drug advertising.
This document discusses inappropriate prescribing in hospitalized elderly patients. It defines inappropriate prescribing as using medications that significantly increase the risk of adverse drug events when safer alternatives exist. Inappropriate prescribing is common in the elderly and associated with increased morbidity, mortality and healthcare costs. Risk factors in hospitals include advanced age, polypharmacy due to multiple comorbidities, and transitions of care involving multiple providers. The document reviews validated tools to evaluate inappropriate prescribing, including Beers Criteria, IPET, STOPP and MAI. It concludes inappropriate prescribing in hospitals is an important public health problem given the aging population.
This document discusses the aggressive marketing tactics used by pharmaceutical companies to promote the use of antidepressants, especially SSRIs like Paxil. It describes how companies expanded disease definitions, ignored safety issues, and promoted the drugs to vulnerable groups like pregnant women to significantly increase profits. The document argues that regulation and information systems have failed and that promotion has become disconnected from science. It calls for learning from these issues to better regulate drug licensing, promotion, and ensure independent information for physicians and consumers.
The document summarizes guidelines for providing information about diseases and prescription medicines to the public in the Netherlands. It outlines the Dutch regulatory system for pharmaceutical advertising and promotion. The guidelines were developed in response to increased disease awareness campaigns and public demand for prescription medicine information. They establish standards for balanced, complete information about diseases and technical information about prescription medicines. The guidelines apply to all parties providing such information and include conditions like not misleading the public or leading to unnecessary medical treatment. A transitional period was provided for adjusting existing information to the new guidelines.
Web only rx16 len wed_1230_1_daugherty_2baier-haasOPUNITE
This document summarizes a presentation on investigating and prosecuting drug-related homicides. It discusses signs that can indicate an overdose death, such as the presence of drugs, track marks, and foam coming from the mouth. It emphasizes treating the death scene like a homicide scene by thoroughly photographing and collecting all potential evidence. This includes searching for drug packaging, needles, phones and surveillance footage. The document also outlines interviewing witnesses to build a timeline and identify the victim's source of drugs. It suggests attempting a controlled buy from suspects to obtain contemporaneous drug samples and strengthen cases.
This document discusses addiction to prescription painkillers and the role that doctors play. It provides background on a 2011 pharmacy shooting committed by David Laffer, a prescription painkiller addict, who had been prescribed over 4,000 pills in the first half of the year. This led to investigations of the prescribing doctors. The document argues that while doctors fulfill their duty to treat patients' pain, they can also indirectly cause addiction. However, addicted patients also manipulate doctors to maintain their drug supply. Therefore, both doctors and patients share blame. It notes the taboo nature of discussing both addiction and doctors' involvement due to the high status of medicine. In the end, some doctors in the Laffer case were arrested, showing that
Relationship Between Drugs and Health Workers - Sample Essaya1customwritings
A1CustomWritings.com are experienced in all academic levels of assignments and in any academic fields, the team of experts of our custom essay writing service have the ability to help you with any requirements of your essay. Our team takes pride in the quality of work provided to our customers and we pledge to do whatever it takes to ensure you receive a paper of only the highest quality.
This document discusses strategies to curb prescription drug abuse, specifically opioid abuse, in West Virginia. It notes that West Virginia has the highest drug overdose mortality rate in the US and clinicians there write a high number of opioid prescriptions. It explores reasons for high prescribing rates and discusses solutions like improving education for patients and doctors, changing financial incentives, using prescription drug monitoring programs, and following CDC guidelines for safer opioid prescribing. Alternative therapies for pain management and the role of EDIE in monitoring patients and interfacing with PDMPs are also covered. The document advocates for internal referrals to pain specialists and multidisciplinary approaches to pain care.
This document discusses drugs for rare diseases. It begins by defining rare diseases according to different organizations. Rare diseases are individually rare but collectively common, affecting around 6-8% of the global population. Developing drugs for rare diseases is challenging due to the small patient populations and high costs. Governments provide incentives like tax breaks and exclusive rights to encourage pharmaceutical companies to develop orphan drugs. Recent advances in genetics have helped identify causes of many rare diseases and accelerated drug development. While treatment options have increased in recent decades, more understanding and viable treatments are still needed for most rare diseases.
This document discusses orphan drugs, which treat rare diseases. It defines orphan drugs and outlines criteria used in the US and EU to designate drugs for rare diseases. Rare diseases affect fewer than 200,000 people in the US and 10,000 in the EU. The Orphan Drug Act of 1983 in the US provided incentives for orphan drug development. Similar laws exist in other countries. Developing orphan drugs is challenging due to low patient populations and high costs. Examples of orphan drugs and their manufacturers are provided. The process for obtaining orphan drug designation is also summarized.
The document summarizes a study examining HIV stigma among opioid-dependent individuals under community supervision. It describes high HIV rates in Washington D.C. and the criminal justice system. The study used a stigma scale to assess stigma in 16 participants. Females and homosexuals reported higher levels of stigma than males and heterosexuals, particularly around disclosure concerns. The study aims to reduce stigma and HIV risk through counseling in Project STRIDE, which provides medication-assisted treatment for opioid dependence and HIV.
The document discusses efforts to address the opioid epidemic in the United States, including:
- Increasing registration and use of prescription drug monitoring programs (PDMPs) to track opioid prescriptions.
- Reducing the stigma around both pain and substance use disorder to increase access to comprehensive treatment.
- Expanding access to naloxone to prevent overdose deaths and "Good Samaritan" legal protections.
- Ongoing education of physicians on safe opioid prescribing and alternative pain management strategies.
This document is an undergraduate thesis that examines the pharmaceutical industry and alternative medicine. It argues that while Western medicine has improved health outcomes for some acute illnesses, the over-reliance on drugs has significant downsides. Preventable medical errors are the third leading cause of death in the US, with pharmaceutical companies more focused on profits than patient safety. The document also suggests that several holistic doctors working on alternative cancer treatments may have been murdered to protect the financial interests of the pharmaceutical industry.
Bacchus 2015 Presentation - Prescription Drugs on College Campuses: A Slipper...Ally Siegler
This presentation was given at The BACCHUS Network General Assembly 2015 by Ally Siegler, Trevor Fain, and Elisabeth Weber. It highlights the growing problem of prescription drug abuse on college campuses and what peer health education programs can do to combat the issue.
Kristen Sismilich created a patient education tool for veterans undergoing chemotherapy at the Baypines VA Hematology/Oncology Clinic. The tool provides pictures and descriptions of common chemotherapy side effects and signs/symptoms that require immediate medical attention. Nurses and patients responded positively to the tool. While the tool still needs approval from the VA, its goal is to improve patient health outcomes and appropriate use of healthcare services by enhancing health literacy as outlined in Healthy People 2020 objectives. Low health literacy is associated with poorer health outcomes and healthcare utilization according to research.
West Virginia has high rates of opioid and benzodiazepine prescription and misuse according to the document. It ranks third highest for opioid prescriptions per capita and first for benzodiazepine prescriptions. In 2014 over 400,000 opioid prescriptions and 300,000 benzodiazepine prescriptions were filled for West Virginia Medicaid recipients. West Virginia Medicaid has policies like quantity limits and a lock-in program to curb prescription drug abuse and encourages providers and recipients to follow best practices for responsible prescribing and use.
Physicians, especially anesthesiologists, face high risks of addiction due to easy access to addictive drugs. While medical boards discipline doctors with reported drug problems, random drug testing is rare, allowing issues to surface only when problems are severe. Addiction to opioids is most common, with fentanyl and sufentanil frequently abused by anesthesiologists due to impaired thinking. More data and proactive random drug testing are needed to address this ongoing problem impacting patient care.
Club Drug Clinic, Project Neptune and the G TrialReShape
This document discusses the Club Drug Clinic and two of its projects: NEPTUNE and the GHB Trial. The Clinic treats patients with issues related to emerging drugs like novel psychoactive substances and club drugs. Project NEPTUNE aims to improve clinical management of these substances through evidence-based guidance. The GHB Trial is a feasibility study testing whether adding the drug baclofen to benzodiazepines improves outcomes for patients withdrawing from GHB dependence.
The document discusses various strategies to reduce unnecessary healthcare costs and improve quality, including reducing overuse of procedures, tests, drugs and hospitalizations through evidence-based guidelines and promoting primary care. It notes that higher spending regions do not achieve better health outcomes and that up to 30% of healthcare spending is wasteful.
The document discusses the prescription drug abuse epidemic in the United States. It provides statistics showing the rise in overdose deaths from prescription painkillers between 1999 and 2008. Certain groups are more at risk of abusing or overdosing on these drugs. "Pill mills" dispensing prescription drugs with little oversight have flourished in Florida, fueling abuse in other states. Efforts are underway to address this crisis and crack down on pill mills.
This document provides an overview of a conference on chronic pain and addiction that will take place from April 10-12, 2012 at Walt Disney World Swan Resort. The conference will focus on prescription drug abuse in the US, the effects of prescription pain medication abuse over time, and advocating for continued education on addiction for pain management providers. Key statistics on prescription drug abuse in the US are presented, including that opioid analgesics are now the leading cause of accidental drug overdose deaths. Abuse of prescription drugs is rising among both adolescents and older adults.
The pharmaceutical industry generates over $145 billion in annual worldwide sales, with the United States representing the largest market. Drug development costs are substantial, though estimates vary significantly. Marketing and profits account for a large portion of pharmaceutical expenditures. Prescription drug costs in the US are the highest in the world due to a lack of price regulation. Many elderly Americans lack adequate drug coverage, negatively impacting health outcomes and costs. Inappropriate self-medication of OTC drugs in children is also common. Generics have increased in market share but remain much cheaper than brand drugs.
This document discusses the use of poison center data to track trends in prescription drug abuse and overdoses. It shows that between 1999-2011, prescription opioid exposures reported to poison centers increased over 150% in the US and 164% in Kentucky. Specific opioids like oxycodone, hydrocodone, and tramadol also increased substantially. Poison center data can provide real-time surveillance to identify emerging problems and formulate strategies to address them.
This study surveyed 36 patients in a residential addiction treatment program to understand the methods used to improperly obtain prescription medications from physicians. Key findings include:
- Patients obtained an average of 50 prescriptions over 3.8 years, seeing an average of 2 doctors in 1.2 different states and 5 pharmacies.
- The most common reasons for obtaining prescriptions from doctors rather than buying illegally were legal concerns and lower cost/increased comfort.
- The most obtained drug types were opioids (97% of patients) and sedative-hypnotics (47% of patients).
- The majority (75%) feigned symptoms to obtain prescriptions, with some using falsified medical records or
Addiction Medicine: Closing the Gap between Science and PracticeCenter on Addiction
These slides accompany CASAColumbia's report, Addiction Medicine: Closing the Gap between Science and Practice, published in June 2012, which found that, despite the prevalence of addiction, the enormity of its consequences, the availability of effective solutions and the evidence that addiction is a disease, both screening and early intervention for risky substance use are rare, and only about 1 in 10 people with addiction involving alcohol or drugs other than nicotine receive any form of treatment.
The document discusses the dangers American patients face from counterfeit medications obtained outside of the regulated US drug supply chain, such as through fake online Canadian pharmacies. It details how breaks in the secure supply chain, such as patients buying drugs online or some doctors and pharmacists obtaining drugs from unlicensed distributors, can endanger patients by exposing them to counterfeit and unsafe medications. The document aims to dispel myths about obtaining cheaper drugs from outside the US and provides tips for patients to stay safe.
This document provides an overview of addiction and substance use. It defines addiction as a chronic disease involving brain circuits, genetics, environment and life experiences. It discusses types of addiction including substance and behavioral addiction. Common addictions include tobacco, alcohol, drugs, gambling, food, video games and internet. The document reviews prevalence data on addiction from various sources. It also discusses treatment approaches for behavioral and substance use disorders including detox, individual therapy, group therapy and rehabilitation programs. Recent studies on substance use during the COVID-19 pandemic are also summarized.
Essential medicines and counterfeit medicinesAmit Bhondve
The document discusses essential medicines and counterfeit medicines. It defines essential medicines as those that satisfy the priority health needs of a population and are selected based on disease prevalence, efficacy, safety and cost-effectiveness. The WHO publishes a Model List of Essential Medicines every two years to guide countries in developing their own lists. Counterfeit medicines pose serious risks as they may contain incorrect ingredients, too much or too little of the active ingredient, or no active ingredient at all. It is difficult to determine the full extent of counterfeiting due to varying reporting methods across countries and regions. Counterfeiting is most prevalent in areas with weak regulatory and enforcement systems for medicines.
Palliative and End of Life Care: Tackling Variations, Eradicating Inequalitiesmckenln
This document summarizes a research program examining end of life care for people with alcohol and drug problems. The program has 5 strands, including a review of existing literature and interviews with key informants in the field. The literature review found little existing research but some indications, including that people with substance abuse problems often die young from "nasty" deaths. Key informant interviews with 17 practitioners highlighted issues like fragmented commissioning and the difficulty predicting needs for this non-homogenous population that experiences high rates of trauma and mental health problems. The research aims to better understand the experiences and needs of those with substance abuse issues at end of life.
This document discusses engaging the medical community on the issue of opioid use and abuse. It begins with introductions from Brian Fingerson, President of Kentucky Professionals Recovery Network, and Dallas Gay, Co-chair of the Medical Association of Georgia Foundation's "Think About It" Campaign. The speakers then review learning objectives about describing changing attitudes around prescription drug abuse, defining clinicians' roles in positively impacting the opioid epidemic, and demonstrating programs that are engaging the clinical community on appropriate opioid use and abuse.
Project Lazarus is a nonprofit organization that provides training and assistance to communities to prevent drug overdoses and meet the needs of those with chronic pain. It believes drug overdoses are preventable if communities take responsibility for their own health. The document discusses drugs involved in overdoses in Jackson County such as opioids, benzodiazepines, and antidepressants. It outlines physical and behavioral signs of prescription drug abuse and provides information on how to properly take, store, dispose of, and never share prescription medications to help create a healthier community.
Similar to Lisa Girion: "Reporting on America’s Opioid Drug Crisis" 4.11.17 (20)
Tom Wong: Public Charge: Immigrant Health Under Trump’s New Rulereportingonhealth
Prof. Tom Wong's slides from the Center for Health Journalism webinar, "Public Charge: Immigrant Health Under Trump’s New Rule" 9.11.19
More info: https://www.centerforhealthjournalism.org/content/employee-health-insurance-failing-americans
Dr. Arnie Milstein: Is Employee Health Insurance Failing Americans?reportingonhealth
The document discusses improving the value of American healthcare over the past 30 years. It notes that while various remedies like managed care plans, consumer directed plans, and accountable care organizations have been tried, healthcare costs still persist too high. The document suggests that large employers need to play a role by steering employees to higher value clinicians and lowering overall prices to finally address the ongoing issue of high healthcare spending in the United States.
Larry Levitt: Is Employee Health Insurance Failing Americans?reportingonhealth
Larry Levitt's slides from the Center for Health Journalism webinar, "Is Employee Health Insurance Failing Americans?" 7.23.19
More info: https://www.centerforhealthjournalism.org/content/employee-health-insurance-failing-americans
Barbara Laker & Wendy Ruderman: "Toxic Cities: Telling Big Stories on Hidden ...reportingonhealth
Barbara Laker and Wendy Ruderman's slides from the Center for Health Journalism webinar, "Toxic Cities: Telling Big Stories on Hidden Risks" 6.6.19
More info: https://www.centerforhealthjournalism.org/content/what-s-stake-rural-america-loses-its-hospitals
Betsy McKay: "What’s at Stake as Rural America Loses Its Hospitals"reportingonhealth
The document discusses the impact of the coronavirus pandemic on the global economy. It notes that the pandemic has caused widespread shutdowns that have had ripple effects across many industries and international supply chains. Major economic forecasts now predict a global recession in 2020 that could be worse than the one seen during the 2008 financial crisis.
Dr. Katy Kozhimannil: "What’s at Stake as Rural America Loses Its Hospitals"reportingonhealth
Dr. Katy Kozhimannil's slides from the Center for Health Journalism webinar, "What’s at Stake as Rural America Loses Its Hospitals" 1.22.19
More info: https://www.centerforhealthjournalism.org/content/what-s-stake-rural-america-loses-its-hospitals
Dr. Elissa Epel: "How Our Environment Gets Under Our Skin"reportingonhealth
This document discusses how social stress from factors like neighborhood conditions, discrimination, and adverse childhood experiences can impact health and aging through biological pathways. Chronic stress gets under the skin by affecting telomere length, inflammation levels, epigenetic aging, and other regulatory systems. Studies show that social stress is associated with shorter telomeres in both human and animal research. Addressing social stress requires efforts at the individual, community, and policy levels to reduce health disparities and promote healthy aging.
Dr. Anthony Iton: "How Our Environment Gets Under Our Skin"reportingonhealth
Dr. Anthony Iton's slides from the Center for Health Journalism webinar, "How Our Environment Gets Under Our Skin" 10.9.18
More info: https://www.centerforhealthjournalism.org/content/master-class-reporting-health-policy
Daniel Chang: "Master Class: Reporting on Health Policy"reportingonhealth
Daniel Chang's slides from the Center for Health Journalism webinar, "Master Class: Reporting on Health Policy" 9.6.18
More info: https://www.centerforhealthjournalism.org/content/master-class-reporting-health-policy
Victoria Colliver: "Master Class: Reporting on Health Policy"reportingonhealth
Victoria Colliver's slides from the Center for Health Journalism webinar, "Master Class: Reporting on Health Policy" 9.6.18
More info: https://www.centerforhealthjournalism.org/content/master-class-reporting-health-policy
Dylan Scott's slides from the Center for Health Journalism webinar, "Putting Medicaid to Work" 7.17.18
More info: https://www.centerforhealthjournalism.org/content/putting-medicaid-work
Angela Rachidi's slides from the Center for Health Journalism webinar, "Putting Medicaid to Work" 7.17.18
More info: https://www.centerforhealthjournalism.org/content/putting-medicaid-work
Judith Solomon's slides from the Center for Health Journalism webinar, "Putting Medicaid to Work" 7.17.18
More info: https://www.centerforhealthjournalism.org/content/putting-medicaid-work
Stephanie Armour: "Will Obamacare survive the latest Trump maneuver?"reportingonhealth
Stephanie Armour's slides from the Center for Health Journalism webinar, "Will Obamacare survive the latest Trump maneuver?" 6.18.18
More info: https://www.centerforhealthjournalism.org/content/obamacare-really-back-legal-limbo
Timothy Jost: "Will Obamacare survive the latest Trump maneuver?"reportingonhealth
Timothy Jost's slides from the Center for Health Journalism webinar, "Will Obamacare survive the latest Trump maneuver?" 6.18.18
More info: https://www.centerforhealthjournalism.org/content/obamacare-really-back-legal-limbo
Dr. Aaron Kesselheim: "Runaway Train: America’s Drug Price Problem"reportingonhealth
Dr. Aaron Kesselheim's slides from the Center for Health Journalism webinar, "Runaway Train: America’s Drug Price Problem," 5.15.18
More info: https://www.centerforhealthjournalism.org/content/runaway-train-americas-drug-price-problem
Katie Thomas: "Runaway Train: America’s Drug Price Problem"reportingonhealth
Katie Thomas' slides from the Center for Health Journalism webinar, "Runaway Train: America’s Drug Price Problem," 5.15.18
More info: https://www.centerforhealthjournalism.org/content/runaway-train-americas-drug-price-problem
David Mitchell: "Runaway Train: America’s Drug Price Problem"reportingonhealth
David Mitchell's slides from the Center for Health Journalism webinar, "Runaway Train: America’s Drug Price Problem," 5.15.18
More info: https://www.centerforhealthjournalism.org/content/runaway-train-americas-drug-price-problem
Lois Beckett: "Outgunned: America’s Public Health Crisis"reportingonhealth
Lois Beckett's slides from the Center for Health Journalism webinar, "Outgunned: America’s Public Health Crisis," 3.13.18
More info: https://www.centerforhealthjournalism.org/content/outgunned-americas-public-health-crisis
David Hemenway: "Outgunned: America’s Public Health Crisis"reportingonhealth
David Hemenway's slides from the Center for Health Journalism webinar, "Outgunned: America’s Public Health Crisis," 3.13.18
More info: https://www.centerforhealthjournalism.org/content/outgunned-americas-public-health-crisis
Summer is a time for fun in the sun, but the heat and humidity can also wreak havoc on your skin. From itchy rashes to unwanted pigmentation, several skin conditions become more prevalent during these warmer months.
Kosmoderma Academy, a leading institution in the field of dermatology and aesthetics, offers comprehensive courses in cosmetology and trichology. Our specialized courses on PRP (Hair), DR+Growth Factor, GFC, and Qr678 are designed to equip practitioners with advanced skills and knowledge to excel in hair restoration and growth treatments.
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdfrightmanforbloodline
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Test bank for karp s cell and molecular biology 9th edition by gerald karp.pdf
Breast cancer: Post menopausal endocrine therapyDr. Sumit KUMAR
Breast cancer in postmenopausal women with hormone receptor-positive (HR+) status is a common and complex condition that necessitates a multifaceted approach to management. HR+ breast cancer means that the cancer cells grow in response to hormones such as estrogen and progesterone. This subtype is prevalent among postmenopausal women and typically exhibits a more indolent course compared to other forms of breast cancer, which allows for a variety of treatment options.
Diagnosis and Staging
The diagnosis of HR+ breast cancer begins with clinical evaluation, imaging, and biopsy. Imaging modalities such as mammography, ultrasound, and MRI help in assessing the extent of the disease. Histopathological examination and immunohistochemical staining of the biopsy sample confirm the diagnosis and hormone receptor status by identifying the presence of estrogen receptors (ER) and progesterone receptors (PR) on the tumor cells.
Staging involves determining the size of the tumor (T), the involvement of regional lymph nodes (N), and the presence of distant metastasis (M). The American Joint Committee on Cancer (AJCC) staging system is commonly used. Accurate staging is critical as it guides treatment decisions.
Treatment Options
Endocrine Therapy
Endocrine therapy is the cornerstone of treatment for HR+ breast cancer in postmenopausal women. The primary goal is to reduce the levels of estrogen or block its effects on cancer cells. Commonly used agents include:
Selective Estrogen Receptor Modulators (SERMs): Tamoxifen is a SERM that binds to estrogen receptors, blocking estrogen from stimulating breast cancer cells. It is effective but may have side effects such as increased risk of endometrial cancer and thromboembolic events.
Aromatase Inhibitors (AIs): These drugs, including anastrozole, letrozole, and exemestane, lower estrogen levels by inhibiting the aromatase enzyme, which converts androgens to estrogen in peripheral tissues. AIs are generally preferred in postmenopausal women due to their efficacy and safety profile compared to tamoxifen.
Selective Estrogen Receptor Downregulators (SERDs): Fulvestrant is a SERD that degrades estrogen receptors and is used in cases where resistance to other endocrine therapies develops.
Combination Therapies
Combining endocrine therapy with other treatments enhances efficacy. Examples include:
Endocrine Therapy with CDK4/6 Inhibitors: Palbociclib, ribociclib, and abemaciclib are CDK4/6 inhibitors that, when combined with endocrine therapy, significantly improve progression-free survival in advanced HR+ breast cancer.
Endocrine Therapy with mTOR Inhibitors: Everolimus, an mTOR inhibitor, can be added to endocrine therapy for patients who have developed resistance to aromatase inhibitors.
Chemotherapy
Chemotherapy is generally reserved for patients with high-risk features, such as large tumor size, high-grade histology, or extensive lymph node involvement. Regimens often include anthracyclines and taxanes.
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
5-hydroxytryptamine or 5-HT or Serotonin is a neurotransmitter that serves a range of roles in the human body. It is sometimes referred to as the happy chemical since it promotes overall well-being and happiness.
It is mostly found in the brain, intestines, and blood platelets.
5-HT is utilised to transport messages between nerve cells, is known to be involved in smooth muscle contraction, and adds to overall well-being and pleasure, among other benefits. 5-HT regulates the body's sleep-wake cycles and internal clock by acting as a precursor to melatonin.
It is hypothesised to regulate hunger, emotions, motor, cognitive, and autonomic processes.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
DECLARATION OF HELSINKI - History and principlesanaghabharat01
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Lisa Girion: "Reporting on America’s Opioid Drug Crisis" 4.11.17
1. The problem
• Drugs--fueled largely by a surge in
prescription overdoses--kill more people each
year than traffic accidents.
• Prescription drug overdose is one of the few
types of preventable death in the U.S. that are
rising.
• Drugs most commonly involved are opioid
painkillers
• CDC calls it an epidemic
2. Conventional wisdom
• The problem is misuse and abuse from a
number of sources:
• "Diversion," pharmacy robberies, internet
• Teenagers/addicts stealing from Grandma's
medicine cabinet
• Teenagers/addicts stealing from medicine
cabinets at open houses
• Teenagers/addicts following old people home
from pharmacy and stealing from their
medicine cabinets
3. Sources
• News stories
• Medical literature
• Government drug abuse survey
• Mortality studies
• Opioid prescribing guides
4. NSDUH
• National Survey on Drug Use and Health:
widely referenced annual query of 70,000
people nationwide.
• More timely and, in some ways, more granular
than other sources, such as CDC mortality
data.
• Focuses on "misuse" and non-medical use.
• Misses some users; dead people don't
answer surveys.
5. NSDUH: painkillers
• Given by or purchased from friend or relative:
66.4%.
• Took from friend or relative without
asking:4.4%.
• Rx from one doctor: 18.1%
• Rx from more than one doctor:1.9%
• Drug dealer or stranger: 3.9%
• Internet: 0.3%
6. Death study
• 2008 study in JAMA looked at about 300
overdose deaths in West Virginia.
• Reported that 63% involved a "diverted" drug,
i.e. the decedent lacked a prescription for at
least one of the implicated meds.
• Did not report % that involved prescribed
drugs.
7. Our study
• 3,733 accidental deaths involving
prescription medications from 2006
through 2011 in Los Angeles, San Diego,
Orange and Ventura counties.
8. Our findings
• In 1,762 cases--47%--one or more drugs
prescribed for the deceased caused or
contributed to the death
9. The prescribers
• 71 doctors had three or more
patients die of prescription-
involved overdoses.
• All but a handful had clean
records.
• The doctor at the top of the
list had16 patients die of
overdoses.
10. The dead
• 71 doctors had total of 298 patients fatally
overdose
• Age range: 21 to 70; average: 48
• They included cops, nurses, teachers, wives,
husbands, mothers and fathers. They lived on
upscale cul-de-sacs, in rural trailer homes and
urban SROs.
• Some took an extra dose because they were
in pain. Many became dependent or addicted
after treatment for real injuries.
12. The sources
• Coroners' reports--including opinion on cause,
investigators' narrative, toxicology results, ID
and demographic info on decedent, prescribed
drugs, prescriber info
• Licensing board records
• National Library of Medicine, U.S. Drug
Enforcement Administration
13. The method
• Collected records on accidental deaths
involving prescription overdose; included a few
suffocations and drownings caused by OD.
• Excluded suicides, traffic accidents and other
trauma-related deaths. Also excluded cases in
which the coroner noted the deceased
overdosed on drugs prescribed for someone
else.
• Cleaned up and organized data; sortable by
key variables, i.e. decedent attributes, cause,
toxicology, prescriber, drugs.